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EFFECTS OF DIETARY SODIUM RESTRICTION IN 
KIDNEY TRANSPLANT RECIPIENTS TREATED WITH 
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
BLOCKADE: A RANDOMIZED CLINICAL TRIAL
Laura V. de Vries
Linn C. Dobrowolski 










BACKGROUND: In patients with chronic kidney disease receiving renin-angioten-
sin-aldosterone system (RAAS) blockade, dietary sodium restriction is an often-used 
treatment strategy to reduce blood pressure (BP) and albuminuria. Whether these 
effects extend to kidney transplant recipients is unknown. We therefore studied the 
effects of dietary sodium restriction on BP and urinary albumin excretion (UAE) in 
kidney transplant recipients receiving RAAS blockade.
STUDY DESIGN: Two-center randomized cross-over trial.
SETTING & PARTICIPANTS: Stable outpatient kidney transplant recipients with cre-
atinine clearance >30 mL/min, BP ≥ 120/80 mmHg, receiving stable RAAS blockade 
therapy.
INTERVENTION: 6-week regular-sodium diet (target, 150 mmol/24h) and a 6-week 
low-sodium diet (target, 50 mmol/24h).
OUTCOMES & MEASUREMENTS: Main outcome parameters were systolic and diastolic 
BP, UAE, and estimated glomerular filtration rate (eGFR) at the end of each diet period. 
Dietary adherence was assessed by 24h urinary sodium excretion.
RESULTS: We randomly assigned 23 kidney transplant recipients, of whom 22 (mean 
age, 58 ± 8 [SD] years; 50% men; mean eGFR, 51 ± 21 mL/min/1.73 m2) completed the 
study. One patient withdrew from the study because of concerns regarding ortho-
static hypotension on the low-sodium diet. Sodium excretion decreased from 164 ± 50 
mmol/24h during the regular-sodium diet to 87 ± 55 mmol/24h during the low-sodium 
diet (mean difference, -77 [95% CI, -110 to -44] mmol/24h; P<0.001). Sodium restric-
tion significantly reduced systolic BP from 140 ± 14 mmHg to 129 ± 12 mmHg (mean 
difference, -11 [95% CI, -14 to -7] mmHg; P<0.001), diastolic BP from 86 ± 8 mmHg to 
79 ± 8 mmHg (mean difference, -7 [95% CI, -10 to -5] mmHg; P<0.001). We found no 
significant effect on natural log (ln)-transformed UAE (mean difference, -0.03 [95% CI, 
-0.6 to 0.6] ln(mg/24h); P=0.9) or eGFR.
LIMITATIONS: No hard end points; small study; small proportion of patients willing 
to test the intervention; adherence to sodium diet was achieved in 86% of patients.
CONCLUSIONS: In stable kidney transplant recipients receiving RAAS blockade, dietary 
sodium restriction effectively reduces BP without affecting eGFR. Dietary sodium restric-
tion is relevant to BP management in kidney transplant recipients receiving RAAS blockade.




Hypertension and albuminuria are common after kidney transplantation and are major 
risk factors for cardiovascular disease and transplant failure in this population.1-3 Up to 
90% of kidney transplant recipients have high blood pressure (BP) or use antihyperten-
sive drugs,4-6 and up to 40% have albuminuria.7,8 In patients with native chronic kidney 
disease (CKD), renin-angiotensin-aldosterone system (RAAS) blockade is the standard 
of care for the treatment of hypertension and albuminuria.9-12 Meanwhile, this class of 
drugs has largely been avoided in kidney transplant recipients because two meta-anal-
yses of otherwise inconclusive data pointed towards an advantage of calcium channel 
blockers instead of RAAS blockers for BP control in this population.13,14 However, this 
view changed recently when data became available from two well-conducted clinical 
trials in kidney transplant recipients suggesting an advantage of prolonged treatment 
with RAAS blockade in kidney transplant recipients.15,16 
High sodium intake has been shown to blunt the antihypertensive and antiproteinuric 
effects of RAAS blockade.17 Interestingly, moderate dietary sodium restriction potenti-
ates RAAS blockade efficacy and effectively reduces BP and proteinuria in patients with 
diabetic18 and nondiabetic CKD.19,20 Moreover, several studies show that low sodium 
intake is associated with much better kidney disease and cardiovascular outcomes 
in patients with CKD.21,22 However, there are indications of a U-shaped association 
of sodium intake with outcomes, with increased risks at both very low and excessive 
sodium intakes.23,24
Therefore, the National Kidney Foundation-Kidney Disease Outcomes Quality Initia-
tive (NKF-KDOQI) and Dietary Approaches to Stop Hypertension (DASH) guidelines 
advocate a maximum sodium intake of 100 mmol/day.10,25 Despite these recommen-
dations, average sodium intake in kidney transplant recipients is about 150 to 200 
mmol/day.26-29 Furthermore, treatment with calcineurin inhibitors and corticosteroids, 
in addition to decreased kidney function and prevalent obesity, may render BP even 
more sodium sensitive in kidney transplant recipients compared with patients with 
CKD in general.30-32 In line with this, a recent cross-sectional study of 660 kidney trans-
plant recipients showed a strong association of sodium intake with BP.26
Therefore, although dietary sodium restriction might have beneficial effects in kidney 
transplant recipients, evidence from clinical trials is lacking. The aim of this randomized 
cross-over clinical trial is therefore to assess the effects of dietary sodium restriction 
on BP and urinary albumin excretion (UAE) in stable outpatient kidney transplant recip-
ients receiving RAAS blockade.
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MATERIALS AND METHODS 
Study Design 
This is a two-center cross-over randomized clinical trial performed at the University 
Medical Center Groningen (UMCG) and the Academic Medical Center Amsterdam, the 
Netherlands, January 2012 to May 2014. The study protocol was in accordance with the 
Declaration of Helsinki and approved by the Institutional Review Board of the UMCG 
(METc 2011/131). The study was conducted according to the guidelines of Good Clinical 
Practice. Written informed consent was obtained from each patient before inclusion. 
The CONSORT (Consolidated Standards of Reporting Trials) checklist was used as a 
reporting reference.33,34
Participants
We screened all kidney transplant recipients who visited the outpatient nephrology 
transplantation clinic of the UMCG and Academic Medical Center Amsterdam and 
who had undergone kidney transplantation at least 1 year before. Kidney transplant 
recipients were invited to participate in the study if they were 18 years or older and 
had stable kidney transplant function with creatinine clearance of at least 30 mL/min 
and BP ≥ 120/80 mmHg. An angiotensin-converting enzyme inhibiter or angiotensin 
receptor blocker had to be part of their antihypertensive regimen. For safety reasons, 
we excluded kidney transplant recipients with systolic BP (SBP) ≥ 180 mmHg or diastolic 
BP (DBP) ≥ 100 mmHg. Other exclusion criteria were use of a calcineurin inhibitor with-
drawal regimen or corticosteroid withdrawal regimen or (suspected) rejection of the 
transplant; accordingly, the immunosuppressive regimen was kept stable throughout 
the study. Furthermore, pregnancy or lactation, active malignancy, insufficient mastery 
of the Dutch language to participate in the study, or participation in another interven-
tion study during or within a month prior to this study were also exclusion criteria.
Immunosuppressive Regimen After Transplantation
Standard immunosuppression consisted of the following: cyclosporine standard for-
mulation (Sandimmune; Novartis Pharma bv; 10 mg/kg; trough levels of 175-200 µg/L 
for the first 3 months, 150-175 µg/L 3-12 months post-transplantation, and 100-150 
µg/L thereafter) combined with prednisolone (starting with 20 mg/day, rapidly tapered 
to 10 mg/day) in kidney transplant recipients who underwent transplantation Janu-
ary 1988 to February 1993; cyclosporine microemulsion (Neoral; Novartis Pharma bv; 
10 mg/kg; trough levels the same as for Sandimmune) and prednisolone in kidney 
transplant recipients who underwent transplantation March 1993 to May 1997; myco-
phenolate mofetil (Cellcept; Roche bv; 2 g/day) was added in May 1997 and used to 
date; tacrolimus (Prograft; Astellas Pharma bv; 0.25 mg/kg; trough levels of 8-12 µg/L 
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for the first 3 months, 6-10 µg/L 3-12 months post-transplantation, and 4-8 µg/L there-
after) replaced cyclosporine as standard therapy in March 2011. 
Dietary Intervention
A schematic overview of the study design is shown in Figure 1. At inclusion, partici-
pants were assigned to a 6-week period of a regular-sodium diet or low-sodium diet. 
A cross-over design was used, such that each patient received 6 weeks of both diets. 
To prevent systematic errors resulting from the cross-over design, diet order was 
assigned randomly. For allocation, a computer-generated list of random numbers was 
used. The study protocol did not include a wash-out period between diet periods 
because one of the study arms was regular sodium intake and the study arms lasted 6 
weeks, making it unlikely that carry-over effects would occur. Sodium intake during the 
low-sodium diet was targeted at 50 mmol/day (~1,200 mg of sodium or 3 g of sodium 
chloride [NaCl] per day). Sodium intake during the regular-sodium diet was targeted at 
150 mmol/day (~3,600 mg of sodium or 9 g of NaCl per day) because average sodium 
intake of kidney transplant recipients in the Netherlands is about 150 mmol/day.6,26 To 
increase feasibility and adherence, participants received individualized dietary counsel-
ing by the research physicians, which focused on remaining as close as possible to the 
participant’s nutritional preferences and habits. During the regular-sodium diet, par-
ticipants were advised to maintain normal habits regarding sodium intake. During the 
low-sodium diet, participants were advised not to add salt to their food and to replace 
sodium-rich products with low-sodium or sodium-free alternatives. In addition, they 
were instructed to maintain an isocaloric diet and stable protein intake. Adherence to 
the sodium diet was monitored by measuring urinary sodium excretion in 24h urine 
samples half-way through and at the end of each 6-week period. To ensure adequate 
24h urine collection, participants were carefully instructed to start 24h urine collection 
with emptying of the bladder, record the time of voiding, and collect all subsequent 
urine through the next 24 hours and include the next morning’s specimen on the day 
of their visit to the outpatient clinic. After each measurement, participants received 
oral feedback on their sodium intake and dietary advice. Adequate adherence to the 
study diet was defined as having at least a 35-mmol reduction in 24h sodium excretion 
(equaling an intake reduction of 2 g of NaCl) from the regular-sodium diet to the low 
sodium diet, based on the difference between 24h sodium excretion assessed at 6 and 
12 weeks. By study design, antihypertensive medication was not changed during the 
study periods unless patients experienced severe orthostatic complaints. If patients 
contacted us with such complaints, they were asked to visit the outpatient clinic, where 
it was decided whether antihypertensive medication had to be reduced based on 
combined information for BP and severity of the complaints.
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Figure 1. Study design. Abbreviations: BP, blood pressure measurement; lab, laboratory 
measurements; U24, 24h urine collection.
Measurements
Measurements were performed at baseline and after 6 and 12 weeks (Figure 1). At 
each visit, fasting blood and 24h urine samples of the preceding day were taken, and 
anthropometry (including height, weight, and waist and hip circumference) and BP 
measurement were performed. Waist and hip circumferences were measured as 
previously described.35 BP was measured at 1-minute intervals for 15 minutes with 
a semiautomatic device (Dinamap; GE Medical Systems) while the patient was left 
alone in a room in a semi-supine position.20,26,36 After 15 minutes of measurements, 
we discarded the last BP measurement to avoid confounding and used the mean of 
the second-to-last 4 readings for analysis of study BP. Blood electrolytes, lipids, and 
proteins and urinary electrolytes were measured by using an automated multianalyzer 
(Modular; Roche Diagnostics). Urinary albumin was measured with a turbidimetric 
assay using benzethonium chloride (Modular). N-Terminal pro-brain natriuretic pep-
tide (NT-proBNP) was measured with a chemiluminescence sandwich immunoassay 
(Elecsys; Roche Diagnostics), aldosterone was measured with a competitive fixed-time 
solid-phase radioimmunoassay (Coat-a-Count; Siemens Medical Solutions Diagnostics), 
and renin was measured with a chemiluminescence sandwich immunoassay (Liaison; 
DiaSorin). Second-center (Academic Medical Center Amsterdam) samples were stored 
at -80°C and analyzed in the UMCG using analytic methods as described. Estimated glo-
merular filtration rate (eGFR) was calculated using the 4-variable MDRD (Modification 
of Diet in Renal Disease) Study equation. Relevant donor and transplantation-related 
characteristics were obtained from patients’ medical records.




Primary outcome parameters were SBP and DBP. The secondary outcome parameter 
was UAE. Tertiary outcome parameters were creatinine clearance, eGFR, serum creati-
nine, body weight, serum sodium, potassium, urea, total cholesterol, NT-proBNP, renin, 
and aldosterone and urinary excretion of urea, calcium, potassium, and creatinine.
Statistical Analysis
Our study was primarily powered to detect an effect on SBP. We calculated a sample 
size of 22 patients (by cross-over design) to detect a difference of 8 mmHg,37 with 
standard deviation of 7 mmHg, in SBP with a power of 90%. A drop-out rate of 10% 
(=2 kidney transplant recipients) was taken into account. Therefore, 24 kidney trans-
plant recipients were intended to be included in the study. Statistical analyses were 
performed with SPSS, version 22.0, for Windows (SPSS Inc) and GraphPad Prism, ver-
sion 5.0 (GraphPad Software Inc). Normally distributed variables are given as mean ± 
standard deviation; non-normally distributed variables, as median and interquartile 
range; and categorical variables as absolute number and percentage. A 2-tailed P<0.05 
was considered statistically significant. We tested for differences between participants 
and non-participants using t tests for normally distributed data, Mann-Whitney U tests 
for non-normally distributed data, and χ2 tests for nominal data. We found no signifi-
cant differences between participants and non-participants in terms of sex, transplant 
vintage, body weight, body mass index, creatinine clearance, eGFR, serum creatinine, 
proteinuria, and sodium intake values. Participants were slightly older compared with 
non-participants (mean age, 58 ± 8 years vs 52 ± 13 years; P=0.004). To estimate the 
effects of sodium restriction on clinical parameters, we used linear mixed-effect models 
for repeated measurements, including a Bonferroni correction, using the unstruc-
tured covariance structure with ‘diet’ and ‘sequence’ as fixed effects and ‘participant’ 
as random effect. Skewed data were logarithmically transformed before statistical 
analysis. We checked for potential carry-over or sequence effects by means of linear 
mixed models with ‘diet’ and ‘sequence’ and their interaction ‘diet x sequence’ as fixed 





Of 181 eligible kidney transplant recipients, 25 gave written informed consent. Of these 
25 kidney transplant recipients, two withdrew consent before randomization. Of the 23 
who were randomly assigned, one patient withdrew halfway through the low-sodium 
period because of orthostatic hypotension (Figure 2). For the primary analysis, we 
analyzed data for all 22 participants who completed the study according to the inten-
tion-to-treat principle. We performed additional per-protocol analyses for the primary 
and secondary outcome parameters, in which we first excluded participants who were 
non-adherent to the study diet (n=19 in analysis), subsequently excluded participants 
who required cessation of 1 or more classes of their antihypertensive medication (n=20 
in analysis), and finally excluded both groups, leaving 17 kidney transplant recipients 
for the final per-protocol analysis.
At baseline, mean age was 58 ± 8 (standard deviation) years, 50% were men, mean 
creatinine clearance was 70 ± 32 mL/min, and median UAE was 40 (interquartile range, 
16-141) mg/24h. All participants used RAAS blockade as antihypertensive treatment, 
and 18 of 22 (82%) used one or more antihypertensive drug beyond RAAS blockade 
(Table 1). All participants used prednisolone as maintenance immunosuppressive ther-
apy, with the addition of cyclosporine (36%) or tacrolimus (18%) and/or mycophenolate 
mofetil (68%) or azathioprine (9%).
Figure 2. Study inclusion flow chart.




Sodium excretion was significantly reduced from 164 ± 50 mmol/24h during the reg-
ular-sodium diet to 87 ± 56 mmol/24h during the low-sodium diet (P<0.001; Table 2). 
This 77-mmol reduction in sodium excretion equaled a reduction of ~2 g of sodium 
or 4.5 g of salt (NaCl) per day. We found no significant change in natural log (ln)-trans-
formed urinary creatinine excretion between the regular- and low-sodium diets (0.0; 
95% CI, -0.1 to 0.1 ln(g/24h); P=0.9; Table 2), indicating accurate 24h urine sample col-
lection. Adherence to the study diet, defined as having at least a 35-mmol reduction 
in 24h sodium excretion from the regular-sodium to the low-sodium diet, based on 
24h sodium excretion at 6 and 12 weeks, was achieved in 19 of 22 (86%) participants.
Primary Outcome Parameter: Blood Pressure
During the regular-sodium diet, mean SBP was 140 ± 14 mmHg and mean DBP was 
86 ± 8 mmHg. Sodium restriction significantly reduced SBP (mean difference, -11 [95% 
CI, -14 to -7] mmHg; P<0.001; Table 2) and DBP (mean difference, -7 [95% CI, -10 to -5] 
mmHg; P<0.001; Table 2). We found no significant carry-over or sequence effects for 
SBP and DBP. Both SBP and DBP decreased in 20 of 22 (91%), remained stable in 1 of 22 
(4.5%), and increased in 1 of 22 (4.5%) participants (Figure 3A-B). Orthostatic hypoten-
sion was present in none of the participants during the regular-sodium diet, whereas 
it was present in 5 participants during the low-sodium diet. Of these 5 participants, 2 
needed tapering of their antihypertensive regimen to resolve the orthostatic hypoten-
sion. In the first of these 2 participants, hydrochlorothiazide dosage was halved to 12.5 
mg once daily, metoprolol dosage was halved to 25 mg twice daily, and treatment with 
doxazosin, 4 mg, was discontinued. In the second, metoprolol dosage was halved to 
50 mg twice daily, and treatment with hydrochlorothiazide, 12.5 mg, was discontinued. 
Both these participants remained on RAAS blockade during the entire study period. 
Finally, one participant withdrew from the study because of orthostatic hypotension.
Secondary Outcome Parameter: Urinary Albumin Excretion
We found no significant reduction in ln(UAE) (mean difference, -0.03 [95% CI, -0.6 to 
0.6] ln(mg/24h); P=0.9; Table 2). We also found no significant carry-over or sequence 
effects for UAE. Individual data show that UAE decreased in 13 of 22 (59%), remained 
stable in 1 of 22 (5%), and increased in 8 of 22 (36%) participants (Figure 3C).
Tertiary Outcome Parameters
We found no significant effect of sodium restriction on creatinine clearance (mean 
difference, -1 [95% CI, -9 to 6] mL/min; P=0.7), eGFR (mean difference, -0.5 [95% CI, 
-0.3 to 2] mL/min/1.73 m2; P=0.7), or natural log-transformed serum creatinine (mean 
difference, 0.02 [95% CI, -0.03 to 0.07] ln(mg/dL); P=0.4; Table 2). Body weight signifi-
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cantly decreased from 83 ± 15 to 81 ± 14 kg (mean difference, -2 [95% CI, -3 to -1] kg; 
P<0.001; Table 2). We found a non-significant increase in plasma renin (P=0.1) and a 
significant increase in plasma aldosterone concentrations (P<0.001; Table 2). Serum 
sodium concentration decreased during dietary sodium restriction, but remained well 
within the reference range (Table 2).
Figure 3. Change in [A] systolic blood pressure (SBP), [B] diastolic blood pressure (DBP), and 
[C] urinary albumin excretion (UAE) for individual kidney transplant recipients in response 
to sodium restriction. Each dot represents an individual patient (N=22). Abbreviations: LS, 
low-sodium diet; RS, regular-sodium diet.
Per-Protocol Analyses
We performed per-protocol analyses for the primary and secondary outcome 
parameters and creatinine clearance, in which we excluded participants with diet 
non-adherence or protocol deviations from the analyses. For SBP and DBP, results 
of the per-protocol analyses were not materially different from those of the primary 
analysis. The same held true for creatinine clearance (Table 3). Interestingly, we found a 
trend between sodium restriction and ln(UAE) after exclusion of participants who were 
non-adherent to the study diet and those who needed cessation of antihypertensive 
medication (mean difference, -0.4 [95% CI, -0.9 to 0.0] ln(mg/24h); P=0.07; Table 3).
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Table 1. Baseline characteristics of intention-to-treat population.
Intention-to-treat population (n=22)
Patient demographics
Age, yrs 58 ± 8
Male sex, n (%) 11 (50)
Body composition 
Height, m 1.74 ± 0.10
Weight, kg 83 ± 14
Hip, cm 103 ± 10
Waist, cm 101 ± 12
BMI, kg/m2 27.1 ± 3.6
Blood pressure
SBP, mmHg 138 ± 15
DBP, mmHg 85 ± 9
Number of antihypertensive drugs 
1, n (%) 4 (18)
2, n (%) 6 (27)
3, n (%) 9 (41)
4, n (%) 3 (14)
Type of antihypertensive drugs 
RAAS blockade, n (%) 22 (100)
Calcium channel blockade, n (%) 6 (27)
β-blockade, n (%) 11 (50)
α-blockade, n (%) 3 (14)
Diuretic, n (%) 12 (55)
Kidney function
Serum creatinine, mg/dL 1.4 [1.2-1.6]
Creatinine clearance, mL/min 70 ± 32
eGFR, mL/min/1.73m2 51 ± 21
Urinary albumin excretion, mg/24h 40 [15-142]
Transplant characteristics
Transplant vintage, yrs 7.3 [3.1-11.5]
Living donor, n (%) 11 (50)
Prior dialysis, n (%) 15 (68)
Immunosuppression
Tacrolimus, n (%) 4 (18)
Cyclosporine, n (%) 8 (36)
Mycophenolate mofetil, n (%) 15 (68)
Azathioprine, n (%) 2 (9)
Prednisolone dose, mg 7.5 [7.5-10]
Values for categorical variables are given as number (percentage); values for continuous variables are given 
as mean ± standard deviation or median [interquartile range]. Conversion factor for units: creatinine in mg/
dL to μmol/L, ×88.4. 
Abbreviations: α, alpha-receptor; β, beta-receptor; BMI, body mass index; DBP, diastolic blood pressure; 




Table 2. Effect of sodium restriction on clinical and biochemical parameters, intention-to-treat 
analysis.
Values after interventiona Treatment effectb
RS (n=22) LS (n=22) LS vs. RS P-value
Sodium excretion, mmol/24h 164 ± 50 87 ± 56 -77 (-110, -44) <0.001
Blood pressure
SBP, mmHg 140 ± 14 129 ± 12 -11 (-14, -7) <0.001
DBP, mmHg 86 ± 8 79 ± 8 -7 (-10, -5) <0.001
Body composition
Weight, kg 83 ± 15 81 ± 14 -2 (-3, -1) <0.001
Hip, cm 104 ± 10 103 ± 9 -0.8 (-1.7, -0.1) 0.06
Waist, cm 101 ± 13 99 ± 11 -2 (-4, 1) 0.1
Kidney function 
Serum creatinine, mg/dL 1.4 [1.2-1.7] 1.4 [1.2-1.8]
ln(serum creatinine), ln(mg/dL) 0.34 ± 0.37 0.36 ± 0.39 0.02 (-0.03, 0.07) 0.4
eGFR, mL/min/1.73m2 50 ± 18 49 ± 20 -0.5 (-0.3, 2) 0.7
Creatinine clearance, mL/min 67 ± 25 66 ± 27 -1 (-9, 6) 0.7
UAE, mg/24h 29 [11-99] 22 [13-94]
ln(UAE), ln(mg/24h) 3.5 ± 1.8 3.4 ± 1.5 -0.03 (-0.6, 0.6) 0.9
Blood 
Sodium, mmol/L 141 ± 4 139 ±4 -2 (-3, -1) 0.003
Potassium, mmol/L 4.1 ± 0.5 4.1 ± 0.6 0.0 (-0.2, 0.2) 0.8
Urea, mmol/L 10.8 ± 4.6 11.5 ± 6.3 0.6 (-0.7, 2.0) 0.3
Albumin, g/L 43 ± 3 44 ± 2 0.4 (-0.8, 1.5) 0.5
Total protein, g/L 68 ± 4 69 ± 4 0.4 (-1.4, 2.2) 0.7
Total cholesterol, mg/dL 196 ± 29 193 ± 32 -4 (-11, 4) 0.3
NT-proBNP, ng/L 133 [71-321] 128 [55-273]
ln(NT-proBNP), ln(ng/L) 5.0 ± 0.9 4.9 ± 1.0 -0.1 (-0.4, 0.1) 0.3
Renin, IU/mL 105 [47-241] 153 [72-337]
ln(Renin), ln(IU/mL) 4.6 ± 1.2 4.8 ± 1.3 0.2 (-0.1, 0.5) 0.1
Aldosterone, pmol/L 276 [149-514] 476 [264-759]
ln(Aldosterone), ln(pmol/L) 5.6 ± 0.9 6.1 ± 0.9 0.5 (0.3, 0.8) <0.001
Urine
Creatinine, g/24h 1.2 [1.1-1.5] 1.3 [1.1-1.5]
ln(Creatinine), ln(g/24h) 0.2 ± 0.3 0.2 ± 0.2 0.0 (-0.1, 0.1) 0.9
Urea, mmol/24h 426 [326-480] 376 [303-432]
ln(Urea), ln(mmol/24h) 6.0 ± 0.3 5.9 ± 0.2 -0.1 (-0.2, 0.0) 0.2
Potassium, mmol/24h 82 [66-104] 71 [57-90]
ln(Potassium), ln(mmol/24h) 4.4 ± 0.3 4.3 ± 0.4 -0.1 (-0.2, 0.0) 0.1
Calcium, mmol/24h 2.5 [1.3-3.8] 1.4 [0.9-3.8]
ln(Calcium), ln(mmol/24h) 0.7 ±1.1 0.6 ±0.9 -0.2 (-0.4, 0.1) 0.3
Variables with a skewed distribution were ln-transformed before analyses. Conversion factors for units: 
creatinine in mg/dL to μmol/L, ×88.4; total cholesterol in mg/dL to mmol/L, ×0.02586.
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LS, low sodium diet; 
NT-proBNP, n-terminal pro-brain natriuretic peptide; RS, regular sodium diet; SBP, systolic blood pressure; 
UAE, urinary albumin excretion. 
a Data are presented as unadjusted mean ± standard deviation or median [interquartile range]. 
b Data are mean differences (95% CI) obtained from linear mixed-effect models for repeated measurements. 
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n RS LS LS vs RS P-value
Systolic blood pressure, mmHg
KTR with diet non-adherence excluded 19 139 ± 14 128 ± 12 -11 (-14, -8) <0.001
KTR with AHT cessation excluded 20 140 ± 15 129 ± 11 -10 (-14, -6) <0.001
Both subgroups above excluded 17 139 ± 14 129 ± 12 -11 (-14, -7) <0.001
Diastolic blood pressure, mmHg
KTR with diet non-adherence excluded 19 86 ± 8 78 ± 8 -8 (-10, -6) <0.001
KTR with AHT cessation excluded 20 87 ± 7 79 ± 7 -8 (-10, -5) <0.001
Both subgroups above excluded 17 86 ± 8 78 ± 7 -8 (-11, -6) <0.001
ln(Urinary albumin excretion), ln(mg/24h)
KTR with diet non-adherence excluded 19 3.4 ± 1.9 3.3 ± 1.5 -0.01 (-0.7, 0.7) 0.9
KTR with AHT cessation excluded 20 3.7 ± 1.7 3.4 ± 1.5 -0.4 (-0.7, 0.0) 0.06
Both subgroups above excluded 17 3.7 ± 1.7 3.2 ± 1.5 -0.4 (-0.9, 0.0) 0.07
Creatinine clearance, mL/min
KTR with diet non-adherence excluded 19 70 ± 25 68 ± 27 -2 (-11, 7) 0.6
KTR with AHT cessation excluded 20 66 ± 25 66 ± 28 0 (-8, 8) 0.9
Both subgroups above excluded 17 69 ± 24 68 ± 28 -1 (-11, 9) 0.9
a Data are presented as unadjusted mean ± standard deviation or median [interquartile range]. 
b Data are mean differences (95% CI) obtained from linear mixed-effect models for repeated measurements. 
Variables with a skewed distribution were ln-transformed before analyses.




To our knowledge, this study is the first randomized cross-over clinical trial to assess 
the effects of dietary sodium restriction on BP and UAE in kidney transplant recipients 
receiving RAAS blockade. In these stable kidney transplant recipients, sodium restric-
tion strongly reduced SBP and DBP, but only had a modest effect on UAE without 
affecting eGFR.
Randomized clinical trials of dietary sodium restriction in kidney transplant recipients 
are scarce. We only found 2 studies that investigated the effects of sodium restriction 
in these patients.37,38 However, these studies did not investigate its effect on top of 
existing RAAS blockade and did not analyze UAE. Soypacaci et al37 followed up 38 kidney 
transplant recipients on a low-sodium diet for 2 weeks and found that a 92-mmol 
reduction in sodium intake resulted in a reduction of 7% in SBP and DBP. Keven et al38 
randomly assigned 32 kidney transplant recipients to low-sodium (n=18) or control 
(n=14) diets for 3 months. An intake difference of 137 mmol between the low-sodium 
and control groups resulted in a difference of 16 mmHg (-12% vs control) in SBP and 
8 mmHg (-10% vs control) in DBP.38 Thus, BP reduction in our study is similar to that 
reported in previous studies of kidney transplant recipients. Our findings are also in 
line with previous randomized cross-over trials in non-transplantation patients with 
kidney disease, in which sodium restriction was studied during RAAS blockade.18-20,39-41
We found a modest effect of sodium restriction on UAE when adherence was ade-
quate, which may be driven by the BP change. However, it must be noted that by 
design, our study was likely underpowered to demonstrate an effect on UAE. More-
over, we found no effect on eGFR, which remained remarkably stable despite rigorous 
sodium restriction and the decrease in BP, whereas in CKD, usually a decrease in GFR is 
observed during sodium restriction and RAAS blockade.18,20,42 Furthermore, we found a 
non-significant increase in plasma renin and significant increase in plasma aldosterone 
concentrations, which is likely a compensatory response to a decrease in effective 
circulating volume caused by the low-sodium diet. Primary increases in aldosterone 
concentrations, which suppress renin concentrations, can result in increases in BP and 
end-organ damage.43 However, in various human conditions of hyperaldosteronism 
secondary to volume depletion (eg, routine low-sodium intake in Yanomami Indians 
or Gitelman or Bartter syndrome with renal sodium loss), hypertension and end-organ 
damage are absent.44,45
The dietary sodium restriction applied here was designed in line with dietary rec-
ommendations for high-risk groups,46,47 to a target of 50 mmol/day. Accordingly, we 
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observed orthostatic hypotension in 5 kidney transplant recipients, which resolved 
by tapering the antihypertensive regimen. Since the time of study design, sodium 
targets have become the subject of debate due to observational studies showing a 
U-shaped association of sodium intake with increasing risks at both very low and 
excessive sodium intakes.23,24,48
The feasibility of persistent sodium reduction in clinical practice remains a discussion 
because current strategies to modify lifestyle (smoking cessation, promoting weight 
loss, and reducing dietary sodium intake) have been found ineffective to date.49 In 
our study, sodium targets were met in the majority (86%) of patients. Similar studies 
to ours showed that an 80- to 100-mmol reduction in sodium intake is feasible in a 
regular nephrology outpatient setting, at least for the duration of the study period.18-20 
There is mounting evidence that persistent lifestyle alterations necessitate a dedicated 
behavioral approach.50-52 Such strategies are not yet included in routine clinical care, 
but are being studied currently (eg, in the SUBLIME [Sodium Burden Lowered by Life-
style Intervention: Self-management and E-Health Technology] Study; ClinicalTrials.
gov study number NCT02132013).53
We acknowledge possible limitations to our study. The main limitation is that we 
investigated short-term effects of sodium restriction on intermediate end points only, 
and we have no data for long-term hard end points such as cardiovascular mortality 
and long-term transplant survival. Also, the number of kidney transplant recipients 
included was relatively small and only a small proportion of the population was willing 
to test the intervention, which potentially affects the generalizability of our results. 
However, our study still seems to be the largest randomized clinical trial assessing the 
effect of dietary sodium restriction on BP and UAE in kidney transplant recipients to 
date. Furthermore, we included only kidney transplant recipients with stable transplant 
function, without overt proteinuria, and with fairly regulated BP. It is unknown whether 
our results can be extrapolated to kidney transplant recipients with chronic allograft 
nephropathy, who generally have more proteinuria and higher BPs. The absence of 
a wash-out period between the low-sodium diet and regular-sodium diet could also 
be a limitation of our study design, but the randomization and long duration of the 
diet periods minimize the likelihood that carry-over effects affected our results. In 
addition, no significant sequence or carry-over effects were detected in linear mixed-
model analyses.
In conclusion, we demonstrate that dietary sodium restriction effectively reduces BP 
in stable kidney transplant recipients receiving RAAS blockade, without affecting eGFR. 
Dietary sodium restriction, therefore, is relevant to BP management in kidney trans-
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plant recipients receiving RAAS blockade. Confirmation studies with hard end points 
are needed to verify whether dietary sodium restriction improves long-term outcome 
in kidney transplant recipients.
ACKNOWLEDGEMENTS 
We thank all kidney transplant recipients and their nephrologists for their willingness 
to participate in this study; Bettine Haandrikman, Jan Roggeveld, and Jeltsje Klooster-
man, UMCG laboratory technicians, for valuable technical support; and Trijntje Kok, 
UMCG dietician, for sharing her knowledge and expertise on sodium-restricted diets.




1.  Halimi JM, Matthias B, Al-Najjar A, et al: Respective predictive role of urinary albumin excretion 
and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 
7(12):2775-2781, 2007
2.  Nauta FL, Bakker SJ, van Oeveren W, et al: Albuminuria, proteinuria, and novel urine biomarkers 
as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis 
57(5):733-743, 2011
3.  Opelz G, Dohler B, Collaborative Transplant Study: Improved long-term outcomes after renal trans-
plantation associated with blood pressure control. Am J Transplant 5(11):2725-2731, 2005
4.  Kasiske BL, Anjum S, Shah R, et al: Hypertension after kidney transplantation. Am J Kidney Dis 
43(6):1071-1081, 2004
5.  Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. 
collaborative transplant study. Kidney Int 53(1):217-222, 1998
6.  Dobrowolski LC, Bemelman FJ, van Donselaar-van der Pant KA, Hoitsma AJ, ten Berge IJ, Krediet CT: 
Treatment efficacy of hypertension in kidney transplant recipients in the netherlands. Neth J Med 
72(5):258-263, 2014
7.  Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al: The risk of cardiovascular disease associated 
with proteinuria in renal transplant patients. Transplantation 73(8):1345-1348, 2002
8. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias 
M: Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. 
Nephrol Dial Transplant 19 Suppl 3:iii47-51, 2004
9.  Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular out-
comes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861-869, 2001
10. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on 
hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 
1):S1-290, 2004
11.  Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of 
nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135(2):73-87, 2001
12.  Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-convert-
ing-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. the heart outcomes 
prevention evaluation study investigators. N Engl J Med 342(3):145-153, 2000
13.  Cross NB, Webster AC, Masson P, O’Connell PJ, Craig JC: Antihypertensives for kidney transplant 
recipients: Systematic review and meta-analysis of randomized controlled trials. Transplantation 
88(1):7-18, 2009
14.  Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA: Renin angiotensin system blockade in 
kidney transplantation: A systematic review of the evidence. Am J Transplant 7(10):2350-2360, 2007
15.  Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E: Effects of ACE inhibitors on long-term 
outcome of renal transplant recipients: A randomized controlled trial. Transplantation 95(6):889-
895, 2013
16.  Ibrahim HN, Jackson S, Connaire J, et al: Angiotensin II blockade in kidney transplant recipients. J 
Am Soc Nephrol 24(2):320-327, 2013
17.  Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric 
efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol 
Dial Transplant 13(7):1682-1685, 1998
Chapter 2
50
18.  Kwakernaak AJ, Krikken JA, Binnenmars SH, et al: Effects of sodium restriction and hydrochlorothia-
zide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial. Lancet Diabetes 
Endocrinol 2(5):385-395, 2014
19.  Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G: Effects of dietary sodium and hydrochloro-
thiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19(5):999-1007, 2008
20.  Slagman MC, Waanders F, Hemmelder MH, et al: Moderate dietary sodium restriction added to 
angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria 
and blood pressure: Randomised controlled trial. BMJ 343:d4366, 2011
21.  Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al: Moderation of dietary sodium potenti-
ates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 
82(3):330-337, 2012
22.  Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P: Sodium intake, ACE inhibition, 
and progression to ESRD. J Am Soc Nephrol 23(1):165-173, 2012
23.  O’Donnell M, Mente A, Rangarajan S, et al: Urinary sodium and potassium excretion, mortality, and 
cardiovascular events. N Engl J Med 371(7):612-623, 2014
24.  Graudal N, Jurgens G, Baslund B, Alderman MH: Compared with usual sodium intake, low- and 
excessive-sodium diets are associated with increased mortality: A meta-analysis. Am J Hypertens 
27(9):1129-1137, 2014
25.  Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and 
the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research 
group. N Engl J Med 344(1):3-10, 2001
26. van den Berg E, Geleijnse JM, Brink EJ, et al: Sodium intake and blood pressure in renal transplant 
recipients. Nephrol Dial Transplant 27(8):3352-3359, 2012
27.  Moeller T, Buhl M, Schorr U, Distler A, Sharma AM: Salt intake and hypertension in renal transplant 
patients. Clin Nephrol 53(3):159-163, 2000
28.  Prasad GV, Huang M, Nash MM, Zaltzman JS: Role of dietary salt intake in posttransplant hyper-
tension with tacrolimus-based immunosuppression. Transplant Proc 37(4):1896-1897, 2005
29.  Ramesh Prasad GV, Huang M, Nash MM, Zaltzman JS: The role of dietary cations in the blood 
pressure of renal transplant recipients. Clin Transplant 20(1):37-42, 2006
30.  Koomans HA, Ligtenberg G: Mechanisms and consequences of arterial hypertension after renal 
transplantation. Transplantation 72(6 Suppl):S9-12, 2001
31.  Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ: Salt sensitivity of blood pressure in chronic 
renal failure. evidence for renal control of body fluid distribution in man. Hypertension 4(2):190-
197, 1982
32.  Hoorn EJ, Walsh SB, McCormick JA, et al: The calcineurin inhibitor tacrolimus activates the renal 
sodium chloride cotransporter to cause hypertension. Nat Med 17(10):1304-1309, 2011
33.  Moher D, Hopewell S, Schulz KF, et al: CONSORT 2010 explanation and elaboration: Updated guide-
lines for reporting parallel group randomised trials. BMJ 340:c869, 2010
34.  Schulz KF, Altman DG, Moher D, CONSORT Group: CONSORT 2010 statement: Updated guidelines 
for reporting parallel group randomized trials. Ann Intern Med 152(11):726-732, 2010
35.  van Ree RM, de Vries AP, Oterdoom LH, et al: Abdominal obesity and smoking are important 
determinants of C-reactive protein in renal transplant recipients. Nephrol Dial Transplant 
20(11):2524-2531, 2005
36.  Navis G, de Jong PE, Donker AJ, van der Hem GK, de Zeeuw D: Moderate sodium restriction in 
hypertensive subjects: Renal effects of ACE-inhibition. Kidney Int 31(3):815-819, 1987
37.  Soypacaci Z, Sengul S, Yildiz EA, et al: Effect of daily sodium intake on post-transplant hypertension 
Sodium Restriction in Renal Transplant Recipients
 51
2
in kidney allograft recipients. Transplant Proc 45(3):940-943, 2013
38.  Keven K, Yalcin S, Canbakan B, et al: The impact of daily sodium intake on posttransplant hyper-
tension in kidney allograft recipients. Transplant Proc 38(5):1323-1326, 2006
39.  McMahon EJ, Bauer JD, Hawley CM, et al: A randomized trial of dietary sodium restriction in CKD. 
J Am Soc Nephrol 24(12):2096-2103, 2013
40.  Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA: Modest salt reduction reduces blood 
pressure and urine protein excretion in black hypertensives: A randomized control trial. Hyperten-
sion 46(2):308-312, 2005
41.  Fine A, Fontaine B, Ma M: Commonly prescribed salt intake in continuous ambulatory peritoneal 
dialysis patients is too restrictive: Results of a double-blind crossover study. J Am Soc Nephrol 
8(8):1311-1314, 1997
42.  Holtkamp FA, de Zeeuw D, Thomas MC, et al: An acute fall in estimated glomerular filtration rate 
during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 
80(3):282-287, 2011
43. Waanders F, de Vries LV, van Goor H, et al: Aldosterone, from (patho)physiology to treatment in 
cardiovascular and renal damage. Curr Vasc Pharmacol 9(5):594-605, 2011
44.  Nowaczynski W, Oliver WJ, Neel JV: Serum aldosterone and protein-binding variables in yanomama 
indians: A no-salt culture as compared to partially acculturated guaymi indians. Clin Physiol Bio-
chem 3(6):289-306, 1985
45.  Calo LA, Puato M, Schiavo S, et al: Absence of vascular remodelling in a high angiotensin-II state 
(bartter’s and gitelman’s syndromes): Implications for angiotensin II signalling pathways. Nephrol 
Dial Transplant 23(9):2804-2809, 2008
46.  Centers for Disease Control and Prevention (CDC): Application of lower sodium intake recommen-
dations to adults--united states, 1999-2006. MMWR Morb Mortal Wkly Rep 58(11):281-283, 2009
47.  McGuire S: Institute of medicine. 2010. strategies to reduce sodium intake in the united states. 
washington, DC: The national academies press. Adv Nutr 1(1):49-50, 2010
48.  Graudal N: The data show a U-shaped association of sodium intake with cardiovascular disease 
and mortality. Am J Hypertens 28(3):424-425, 2015
49.  van Zuilen AD, Bots ML, Dulger A, et al: Multifactorial intervention with nurse practitioners does not 
change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 82(6):710-717, 
2012
50.  Cook NR, Cutler JA, Obarzanek E, et al: Long term effects of dietary sodium reduction on cardiovas-
cular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). 
BMJ 334(7599):885-888, 2007
51.  Robare JF, Bayles CM, Newman AB, et al: The “10 keys” to healthy aging: 24-month follow-up results 
from an innovative community-based prevention program. Health Educ Behav 38(4):379-388, 2011
52.  Zhang SX, Guo HW, Wan WT, Xue K: Nutrition education guided by dietary guidelines for chinese 
residents on metabolic syndrome characteristics, adipokines and inflammatory markers. Asia Pac 
J Clin Nutr 20(1):77-86, 2011
53.  Humalda JK, Navis G: Dietary sodium restriction: A neglected therapeutic opportunity in chronic 
kidney disease. Curr Opin Nephrol Hypertens 23(6):533-540, 2014

